<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02695290</url>
  </required_header>
  <id_info>
    <org_study_id>1200.208</org_study_id>
    <nct_id>NCT02695290</nct_id>
  </id_info>
  <brief_title>Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)</brief_title>
  <official_title>An Open-label, Single-arm Phase IV Study of Afatinib in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Who Have Poor Performance Status and Whose Tumors Have the Common Epidermal Growth Factor Receptor (EGFR) Mutations, Exon 19 Deletions or Exon 21(L858R) Substitution Mutations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      There is a medical need for improving treatment of poor performance status patients with EGFR&#xD;
      driver mutations and documenting safety and tolerability of existing agents.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date type="Actual">March 17, 2016</start_date>
  <completion_date type="Actual">August 26, 2016</completion_date>
  <primary_completion_date type="Actual">August 26, 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Patients With Occurrence of Adverse Events (AEs) Leading to Dose Reduction of Afatinib</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>Percentage of patients with occurrence of Adverse Events (AEs) leading to dose reduction of afatinib.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Patients With Occurrence of CTCAE Grade 3 or Higher Diarrhoea, Rash/Acne+, Stomatitis+ and Paronychia+ (+ Represents Grouped Term)</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>Percentage of patients with occurrence of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher diarrhoea, rash/acne+, stomatitis+ and paronychia+ (+ represents grouped term).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to First Dose Reduction of Afatinib Caused by Adverse Events (AEs)</measure>
    <time_frame>Up to 98 days</time_frame>
    <description>Time to first dose reduction of afatinib caused by Adverse Events (AEs) defined as time from the date of the first administration of afatinib to the first dose reduction of afatinib caused by AEs.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Carcinoma, Non-Small-Cell Lung</condition>
  <condition>ErbB Receptors</condition>
  <arm_group>
    <arm_group_label>Afatinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <arm_group_label>Afatinib</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  Pathologically or cytologically confirmed NSCLC&#xD;
&#xD;
          -  Stage IV Cancer (includes cytologically proven pleural effusion or pericardial&#xD;
             effusion) or recurrent disease. The staging is based on American Joint Committee on&#xD;
             Cancer (AJCC) Tumor Node Metastatic (TNM) classification of malignant tumors, 7th&#xD;
             edition&#xD;
&#xD;
          -  Evidence of common EGFR activating mutations (Del 19 and/or L858R)&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or 3&#xD;
&#xD;
          -  Adequate organ function, defined as all of the following:&#xD;
&#xD;
          -  Absolute neutrophil count (ANC) &gt; 1500 / mm3&#xD;
&#xD;
          -  Platelet count &gt;75,000 / mm3.&#xD;
&#xD;
          -  Baseline creatinine of &lt; or = 1.5 g/dl or, if &gt; 1.5, an estimated creatinine clearance&#xD;
             of &gt; 45 ml/min&#xD;
&#xD;
          -  Total Bilirubin &lt; 1.5 times upper limit of institutional normal (ULN)&#xD;
&#xD;
          -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) &lt; three times ULN&#xD;
             (if related to liver metastases &lt; five times ULN)&#xD;
&#xD;
          -  Recovery from any previous therapy related toxicity to&lt; or = Grade 1 at study entry&#xD;
             (except for stable sensory neuropathy &lt; or =Grade 2 and alopecia)&#xD;
&#xD;
          -  Life expectancy of at least three months&#xD;
&#xD;
          -  Written informed consent that is consistent with International Council on&#xD;
             Harmonization- Good Clinical Practice (ICH-GCP) guidelines&#xD;
&#xD;
          -  Age 18 or older&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Prior participation in an afatinib clinical study, even if not assigned to afatinib&#xD;
             treatment&#xD;
&#xD;
          -  Prior systemic therapy for metastatic or recurrent NSCLC including prior treatment&#xD;
             with EGFR targeting small molecules or antibodies. Note: radiotherapy alone and&#xD;
             adjuvant/neoadjuvant treatment is not counted as a line of therapy.&#xD;
&#xD;
          -  Concurrent investigational therapy or investigational therapy within 4 weeks of start&#xD;
             of afatinib therapy&#xD;
&#xD;
          -  Radiotherapy within 4 weeks prior to start of study treatment, except as follows:&#xD;
&#xD;
             i.) Palliative radiation to target organs other than chest may be allowed up to 2&#xD;
             weeks prior to study treatment, or ii.) Single dose palliative treatment (e.g&#xD;
             Stereotactic Radio Surgery(SRS) or Stereotactic Body Radiation Therapy) (SBRT) for&#xD;
             symptomatic metastasis outside above allowance to be discussed with sponsor prior to&#xD;
             enrolling.&#xD;
&#xD;
          -  Major surgery within 4 weeks before starting study treatment or scheduled for surgery&#xD;
             during the projected course of the study&#xD;
&#xD;
          -  Women of child-bearing potential (WOCBP) and men who are able to father a child, or&#xD;
             use adequate contraception prior to study entry, for the duration of study&#xD;
             participation and for at least 28 days after treatment has ended.&#xD;
&#xD;
          -  Presence of an active infection or with a fever &gt; 38.5 C within 3 days of the first&#xD;
             scheduled day of dosing&#xD;
&#xD;
          -  Known hypersensitivity to afatinib or the excipients of afatinib&#xD;
&#xD;
          -  Known pre-existing interstitial lung disease&#xD;
&#xD;
          -  Pathologically documented meningeal carcinomatosis (i.e. cytology (+) lumbar puncture&#xD;
             ; radiology reports alone raising this as a possibility, in the absence of true&#xD;
             symptomatology, would not constitute an exclusion)&#xD;
&#xD;
          -  Presence of brain or subdural metastases, unless local therapy has been completed and&#xD;
             use of corticosteroids has been discontinued or the dose has been stable for at least&#xD;
             4 weeks before starting study treatment. Any symptoms attributed to brain metastases&#xD;
             must be stable for at least 4 weeks before starting study treatment (Pts post SRS can&#xD;
             be enrolled earlier as long as their symptoms are stable or improved and they are off&#xD;
             steroids)&#xD;
&#xD;
          -  Previous or concomitant malignancies at other sites, except effectively treated&#xD;
             non-melanoma skin cancers, carcinoma in situ of the cervix, ductal carcinoma in situ&#xD;
             or effectively treated malignancy that has been in remission for more than 2 years and&#xD;
             is considered to be cured&#xD;
&#xD;
          -  History or presence of clinically relevant cardiovascular abnormalities such as&#xD;
             uncontrolled hypertension, congestive heart failure New York Heart Association (NYHA)&#xD;
             classification of 3 or 4 unstable angina or poorly controlled arrhythmia as determined&#xD;
             by the investigator. Myocardial infarction within 6 months prior to treatment with&#xD;
             afatinib.&#xD;
&#xD;
          -  Any history or presence of poorly controlled gastrointestinal disorders that could&#xD;
             affect the absorption of the study drug (e.g. Crohn's disease, ulcerative colitis,&#xD;
             chronic diarrhoea, malabsorption)&#xD;
&#xD;
          -  Known or suspected active hepatitis B (Hep B) infection (defined as presence of HepB&#xD;
             (surface Antigen) sAg and/ or Hep B DNA), active hepatitis C infection (defined as&#xD;
             presence of Hep C RNA) and/or known HIV carrier&#xD;
&#xD;
          -  Any history of or concomitant condition that, in the opinion of the Investigator,&#xD;
             would compromise the patient's ability to comply with the study or interfere with the&#xD;
             evaluation of the safety and efficacy of the test drug&#xD;
&#xD;
          -  Treatment with any of the prohibited concomitant medications that cannot be stopped&#xD;
             for the duration of trial participation&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Boehringer Ingelheim</last_name>
    <role>Study Chair</role>
    <affiliation>Boehringer Ingelheim</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>1200.208.10032 Boehringer Ingelheim Investigational Site</name>
      <address>
        <city>Fountain Valley</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>September 2017</verification_date>
  <study_first_submitted>February 25, 2016</study_first_submitted>
  <study_first_submitted_qc>February 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 1, 2016</study_first_posted>
  <results_first_submitted>August 9, 2017</results_first_submitted>
  <results_first_submitted_qc>September 15, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">September 18, 2017</results_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>This was an open-label, single-arm Phase IV study of afatinib in patients with stage IV or recurrent Non-Small Cell Lung Cancer who have poor performance status and whose tumors have the common epidermal growth factor receptor (EGFR) mutations, Exon 19 deletions or Exon 21(L858R) substitution mutations.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Afatinib</title>
          <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Patients who receive at least one dose of afatinib will be included in the treated set. All data collected from the single patient who received study medication.</population>
      <group_list>
        <group group_id="B1">
          <title>Afatinib</title>
          <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="62" spread="NA">Not Applicable as only one patient was treated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Patients With Occurrence of Adverse Events (AEs) Leading to Dose Reduction of Afatinib</title>
        <description>Percentage of patients with occurrence of Adverse Events (AEs) leading to dose reduction of afatinib.</description>
        <time_frame>Up to 98 days</time_frame>
        <population>Patients who receive at least one dose of afatinib will be included in the treated set.All data collected from the single patient who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Occurrence of Adverse Events (AEs) Leading to Dose Reduction of Afatinib</title>
          <description>Percentage of patients with occurrence of Adverse Events (AEs) leading to dose reduction of afatinib.</description>
          <population>Patients who receive at least one dose of afatinib will be included in the treated set.All data collected from the single patient who received study medication.</population>
          <units>Pecentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="NA" upper_limit="NA">Confidence interval is not calculable as only one patient is analyzed.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Patients With Occurrence of CTCAE Grade 3 or Higher Diarrhoea, Rash/Acne+, Stomatitis+ and Paronychia+ (+ Represents Grouped Term)</title>
        <description>Percentage of patients with occurrence of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher diarrhoea, rash/acne+, stomatitis+ and paronychia+ (+ represents grouped term).</description>
        <time_frame>Up to 98 days</time_frame>
        <population>Patients who receive at least one dose of afatinib will be included in the treated set.All data collected from the single patient who received study medication. All data collected from the single patient who received study medication.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Patients With Occurrence of CTCAE Grade 3 or Higher Diarrhoea, Rash/Acne+, Stomatitis+ and Paronychia+ (+ Represents Grouped Term)</title>
          <description>Percentage of patients with occurrence of Common Terminology Criteria for Adverse Events (CTCAE) grade 3 or higher diarrhoea, rash/acne+, stomatitis+ and paronychia+ (+ represents grouped term).</description>
          <population>Patients who receive at least one dose of afatinib will be included in the treated set.All data collected from the single patient who received study medication. All data collected from the single patient who received study medication.</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Dose Reduction of Afatinib Caused by Adverse Events (AEs)</title>
        <description>Time to first dose reduction of afatinib caused by Adverse Events (AEs) defined as time from the date of the first administration of afatinib to the first dose reduction of afatinib caused by AEs.</description>
        <time_frame>Up to 98 days</time_frame>
        <population>All data collected from the single patient who received study medication. As none of the AEs led to the dose reduction hence time to first dose reduction is not applicable.</population>
        <group_list>
          <group group_id="O1">
            <title>Afatinib</title>
            <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Dose Reduction of Afatinib Caused by Adverse Events (AEs)</title>
          <description>Time to first dose reduction of afatinib caused by Adverse Events (AEs) defined as time from the date of the first administration of afatinib to the first dose reduction of afatinib caused by AEs.</description>
          <population>All data collected from the single patient who received study medication. As none of the AEs led to the dose reduction hence time to first dose reduction is not applicable.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first drug administration until 40 days after the last dose of study medication, up to 98 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Afatinib</title>
          <description>Subject received Giotrif® / Gilotrif® (Afatinib) with starting dose of 30 milligram (mg) orally, once daily until progression or occurrence of intolerable adverse event (AE) or end of trial.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Boehringer Ingelheim (BI) acknowledges that investigators have the right to publish the study results. Investigators shall provide BI with a copy of any publication or presentation for review prior to any submission. Such review will be done with regard to proprietary information, information related to patentable inventions, medical, scientific, and statistical accuracy within 60 days. BI may request a delay of the publication in order to protect BI's intellectual property rights.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>This study was stopped prematurely when only 1 patient had received afatinib treatment so it was not possible to draw any conclusion.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Boehringer Ingelheim, Call Center</name_or_title>
      <organization>Boehringer Ingelheim</organization>
      <phone>1-800-243-0127</phone>
      <email>clintriage.rdg@boehringer-ingelheim.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

